Late clinical-stage biopharmaceutical company, Outlook Therapeutics, Inc., is honing in on the development and commercialization of monoclonal antibodies within the ophthalmic industry. With a specific focus on wet age-related macular degeneration and various retinal diseases, Outlook Therapeutics' main product candidate, ONS-5010, is currently in Phase-III clinical trials. Collaborative partnerships and licensing agreements with IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. further solidify Outlook Therapeutics' standing within the industry. Formerly known as Oncobiologics, Inc., the company rebranded in November 2018 as Outlook Therapeutics, Inc. Outlook Therapeutics, Inc. is headquartered in Iselin, New Jersey and was established in 2010.